Categories: HealthcareNews

PetMed Express, Inc. to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

DELRAY BEACH, Fla., Aug. 21, 2024 (GLOBE NEWSWIRE) — PetMed Express, Inc., dba PetMeds and parent company of PetCareRx, (Nasdaq: PETS), will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference, to be held September 4-6, 2024 in New York.

Sandra Campos, CEO and President, will hold a fireside chat on September 6, 2024 at 7:45 a.m. (Eastern Time). A live audio webcast of the fireside chat will be available on the “Events & Presentations” section of PetMed’s investor relations website at https://investors.petmeds.com. After the event, a replay of the fireside chat will be archived and available on this same website for approximately 90 days.

About PetMed Express, Inc.

Founded in 1996, PetMeds is a leader in the digital pet pharmacy industry. As a national online retailer, PetMeds.com and PetCareRx.com are top choices for delivering preventive and chronic symptom prescriptions and OTC medications and products through their thousands of veterinary partners and a loyal customer base. Leveraging telehealth and insurance partnerships, they offer unparalleled value and convenience to pet parents at every stage of their pets’ lives, whether dogs, cats, or horses. PetMeds and PetCareRx provide a comprehensive range of medications, food products, and essential supplies through their websites, www.PetMeds.com and www.PetCareRx.com.

Investor Contact:
ICR, LLC
John Mills
(646) 277-1254
Reed Anderson
(646) 277-1260
investor@petmeds.com

Staff

Recent Posts

George Medicines demonstrates potential of novel, low-dose, triple combination pill to transform management of hypertension in Hot Line Session at ESC Congress 2024

George Medicines demonstrates potential of novel, low-dose, triple combination pill to transform management of hypertension…

3 hours ago

Junshi Biosciences Announces 2024 Interim Financial Results and Provides Corporate Updates

SHANGHAI, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX:…

3 hours ago

Avricore Grants Options

VANCOUVER, British Columbia, Aug. 30, 2024 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the…

3 hours ago

Vision Sensing Acquisition Corp. Announces Intention to Extend the Period to Consummate Its Initial Business Combination to October 3, 2024

NEW YORK, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC,…

3 hours ago

Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib

Proceeds to be used for development of lead compound tuspetinib in combination therapy as frontline…

3 hours ago

Jushi Holdings Inc. Announces Filing of Canadian Preliminary Base Shelf Prospectus

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES…

3 hours ago